U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07145177) titled '177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer' on Aug. 20.
Brief Summary: This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastases amenable to liver-directed therapy who have progressed on at least one prior androgen pathway inhibitor.
Study Start Date: Oct. 31
Study Type: INTERVENTIONAL
Condition:
Metastatic Prostate Cancer
Prostate Cancer
...